Proteimax says it has developed a unique peptide discovery method that led to a platform comprising 54 natural micro-peptides, and the company is already talking like it has cracked something bigger than medicine. The pitch is polished. The machinery behind it is less glamorous: patents, approvals, marketing partners, and a commercial rollout built to turn biological research into a product line.
The Corporate Cure
The company says the platform contains an extensive network of sensors and receptors and rests on more than 20 years of foundational biological research on intracellular peptides that regulate cellular function. Guy Fishkin wrote the piece in collaboration with Proteimax, and it was published at 02:49 PM on July 01 2026 IDT. That detail matters. So does the sponsorship. The article is not a neutral dispatch from the lab bench; it is a company narrative with a byline attached.
Proteimax identifies itself as a local biotech company that has been active internationally for 7 years, in a global healthcare industry it says is being revolutionized by metabolic health. The company says its discovery is backed by dozens of patents on molecules and production methods. It was co-founded by Dr. Andrea S. Heimann, Chief Science Officer, and Prof. Hammar Pró, both biotechnology scientists from Brazil who made aliyah to Israel, along with Dr. Arnon Krongrad, an American physician and scientist, and Nimrod Elmish, the company’s CEO. The structure is familiar: science, capital, patents, and a state-linked market waiting for the product.
Elmish says, “The medical world now understands that peptides — the protein building blocks we have discovered —are able to carry messages and commands that the body can read and understand. We are talking about 54 building blocks, each responsible for a different aspect of health.” He says PEP19, the company’s first peptide, is already commercialized in the United States and Brazil after a series of successful trials, including in humans, and a series of approvals meeting FDA standards that granted it GRAS status and classification as a safe food supplement with no side effects.
From Lab Claims to Market Channels
Elmish says PEP19 sends “an immediate command to all fat cells,” signaling that the body is in an “extreme state” and must use stubborn fat reserves and convert them into an energy source. He says experiments on mammals at particularly low temperatures, including in ice water, provided insights into the human body and led to extraordinary discoveries. He also says human trials showed the peptide acts directly on fat cells rather than through brain signaling pathways and can achieve health benefits. The company says the optimal use is a daily capsule taken before sleep, without changing lifestyle habits, diet, or injections, and without side effects.
The article says controlled clinical trials in humans produced a 17% reduction in abdominal fat, a 23% reduction in insulin resistance, a 6% reduction in HbA1c levels, and a 35% improvement in sleep quality. Elmish says the peptide can simultaneously combat heart attacks, high blood pressure, high blood sugar levels, and peripheral fat, and that daily use may improve those measures. The claims are sweeping. The sales logic is simple. One capsule, many promises.
Elmish says PEP19 is intended for millions of people who want to improve their metabolic health, including those with excess visceral fat or prediabetes, people who want to support their metabolism as part of a healthy lifestyle, and GLP-1 patients seeking support throughout the process or afterward. The article says peptides are considered the next big thing in healthcare outside Israel and are offered in various settings beyond primary care physicians. It says that in the United States, prescriptions for peptides, including GLP-1, can be obtained over the phone by a nurse or a doctor. The medical system here looks less like care and more like a distribution network.
The State, the Market, and the Bottleneck
Proteimax is expanding its global marketing and distribution efforts alongside the launch of PEP19 in the United States, where it has been marketed in recent months as a dietary supplement. It says the company is building a network of distribution and marketing partners, as well as partnerships for mass production and raw material refinement. The article says the company is at its commercial stage after a total raise of approximately $5.5 million, including $4 million from a Series A round that closed earlier this year.
The Brazilian Ministry of Health launched a major trial involving approximately 1,000 people using PEP19 after positive clinical results among patients with chronic hepatic fat, with the goal of optimizing dosing for users with different indications before possible incorporation into the SUS, the Brazilian Unified Health System, as a therapeutic alternative. That’s the public sector entering the pipeline after the private one has already set the terms.
Elmish says Israel is not a priority for the company at this stage, calling it “a land of impossible restrictions” and saying the Ministry of Health erects bureaucratic walls for years, including the need to obtain kashrut approvals from the Ministry of Religious Affairs. The company’s own chief executive frames the state as an obstacle course of permits and religious gatekeeping. The market, meanwhile, keeps moving.
The broader vision includes remaining peptides expected to reach the market over the coming decade. Elmish says the second peptide, PEP44, is focused on selectively “killing” any rapidly dividing cell in the body and is expected to provide an unprecedented solution for cancer diseases. He says the third peptide, PEP51, will address neurological diseases and act to restore the central nervous system, which could help treat diseases like Alzheimer’s and, in the long term, extend life expectancy by more than 50 years.
Elmish says the company stayed quiet for many years to complete patents and FDA approvals and avoid the spotlight. He says the company did not want giant pharmaceutical companies to realize it was presenting a single-capsule solution for a large share of the world’s pharmaceutical revenues in the future. That’s the real grammar of the piece: not public health, but capture, exclusivity, and the scramble over future revenue streams dressed up as salvation.
The article says peptides have become one of the most exciting areas in biotechnology and pharmaceuticals in recent years and that a discovery of an innovative peptide that has demonstrated significant results in humans is rare and attracts interest from pharmaceutical, dietary supplement, cosmetics, and functional food companies worldwide. The language of breakthrough does a lot of work here. So do the patents, the approvals, and the distribution deals. The body gets the capsule. The market gets the rest.